Atea Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Atea Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

Atea Pharmaceuticals: 12 sponsored US clinical trials, 2 recruiting.

Atea Pharmaceuticals sponsors 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatic Impairment, with 2 trials.

Top-decile sponsor footprint

Atea Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 1

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320
RECRUITING Phase 1

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346
ACTIVE NOT RECRUITING Phase 3

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

NCT06868264
COMPLETED Phase 1

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

NCT07007806
COMPLETED Phase 1

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

NCT06204679
COMPLETED Phase 2

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

NCT05904470
COMPLETED Phase 1

The Study of Bemnifosbuvir in Healthy Japanese Subjects

NCT05905497
COMPLETED Phase 1

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

NCT05724693
COMPLETED Phase 3

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

NCT05629962
TERMINATED Phase 1

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

NCT05366439
COMPLETED Phase 1

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

NCT05004415
TERMINATED Phase 2

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

NCT04396106

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 2
Phase 3 2

Therapeutic Areas

Hepatic Impairment 2
Healthy Volunteer Study 2
Hepatic Cirrhosis 1
Chronic Hepatitis C Virus 1
Hepatitis C Virus Chronic Infection 1
Hepatitis C, Chronic 1
HCV 1
Hepatitis C 1
Renal Impairment 1
Healthy Volunteer 1

What is open in the Atea Pharmaceuticals pipeline

2 recruiting of 12 indexed (17% open); 7 completed (58%).

Phase mix: 2 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Hepatic Impairment (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Atea Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 12 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Atea Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%5%10%15%20% Total trials Recruiting share Atea PharmaceuticalsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAdageneAgendiaAkamis BioAnthos Therapeutics
Atea Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Atea Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Atea Pharmaceuticals page

12 registered trials is a research-attention snapshot, not an endorsement of Atea Pharmaceuticals or any single study.

  • 2 of Atea Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hepatic Impairment is the condition Atea Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatic Impairment trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Atea Pharmaceuticals pipeline card: 12 registered trials from official public datasets.Report a data error.